Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
P/E ratio for Prenetics Global Limited (PRE)
P/E ratio as of 2023: -1.06
According to Prenetics Global Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.06. At the end of 2022 the company had a P/E ratio of -0.80.
P/E ratio history for Prenetics Global Limited from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.06 |
| 2022 | -0.80 |
| 2021 | -7.80 |
| 2020 | -439.38 |
| 2019 | -42.73 |